Sporadic adult-onset hypophosphatemic osteomalacia caused by excessive action of fibroblast growth factor 23. 2008

Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
Department of General Internal Medicine, Ohta-Nishinouchi Hospital, Koriyama. gim-hoshino@ohta-hp.or.jp

A 50-year-old man without family history of metabolic bone disease was referred to our hospital with a 5-year history of progressively worsening spinal and bilateral diffuse leg pain and proximal muscle weakness. Two years before admission, he was diagnosed as ankylosing spondylitis by a rheumatologist and was maintained on low-dose prednisone therapy without benefit. He developed progressive spinal and thoracic deformities, resulting in a 10 cm loss in height in the preceding 2 years. On physical examination, marked thoracic kyphosis and pectus carinatum was noted. Plain radiograph revealed pseudofracture in the right femoral neck. Laboratory findings showed a normal level of serum calcium, elevated level of serum alkaline phosphatase and inappropriately increased urinary phosphate excretion despite extreme hypophosphatemia. He was diagnosed as adult-onset hypophosphatemic osteomalacia caused by renal phosphate wasting. Serum fibroblast growth factor 23 was the upper limit of normal despite extreme hypophosphatemia and no neoplastic lesion potentially inducing hypophosphatemic osteomalacia could be identified in a thorough search including imaging studies of his entire body. Oral administration of phosphate and activated vitamin D together with dipyridamole relieved the persistent pain and weakness, and he became fully ambulatory.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010018 Osteomalacia Disorder caused by an interruption of the mineralization of organic bone matrix leading to bone softening, bone pain, and weakness. It is the adult form of rickets resulting from disruption of VITAMIN D; PHOSPHORUS; or CALCIUM homeostasis. Adult Rickets,Rickets, Adult
D010710 Phosphates Inorganic salts of phosphoric acid. Inorganic Phosphate,Phosphates, Inorganic,Inorganic Phosphates,Orthophosphate,Phosphate,Phosphate, Inorganic
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D004176 Dipyridamole A phosphodiesterase inhibitor that blocks uptake and metabolism of adenosine by erythrocytes and vascular endothelial cells. Dipyridamole also potentiates the antiaggregating action of prostacyclin. (From AMA Drug Evaluations Annual, 1994, p752) Antistenocardin,Apo-Dipyridamole,Cerebrovase,Cléridium,Curantil,Curantyl,Dipyramidole,Kurantil,Miosen,Novo-Dipiradol,Persantin,Persantine,Apo Dipyridamole,Novo Dipiradol
D005346 Fibroblast Growth Factors A family of small polypeptide growth factors that share several common features including a strong affinity for HEPARIN, and a central barrel-shaped core region of 140 amino acids that is highly homologous between family members. Although originally studied as proteins that stimulate the growth of fibroblasts this distinction is no longer a requirement for membership in the fibroblast growth factor family. DNA Synthesis Factor,Fibroblast Growth Factor,Fibroblast Growth Regulatory Factor,Growth Factor, Fibroblast,Growth Factors, Fibroblast
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000089703 Fibroblast Growth Factor-23 A specific fibrobroblast growth factor that is primarily synthesized by OSTEOCYTES and OSTEOBLASTS. It is involved in regulating phosphate homeostasis and renal phosphate excretion. Fibroblast Growth Factor 23
D014807 Vitamin D A vitamin that includes both CHOLECALCIFEROLS and ERGOCALCIFEROLS, which have the common effect of preventing or curing RICKETS in animals. It can also be viewed as a hormone since it can be formed in SKIN by action of ULTRAVIOLET RAYS upon the precursors, 7-dehydrocholesterol and ERGOSTEROL, and acts on VITAMIN D RECEPTORS to regulate CALCIUM in opposition to PARATHYROID HORMONE.

Related Publications

Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
December 2001, Endocrine journal,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
April 2024, Endocrinology and metabolism (Seoul, Korea),
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
October 2005, Nihon rinsho. Japanese journal of clinical medicine,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
August 1989, Singapore medical journal,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
November 2005, Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
May 2010, Chinese medical journal,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
January 2012, Internal medicine (Tokyo, Japan),
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
March 2023, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
June 1997, Orvosi hetilap,
Chisho Hoshino, and Noriyuki Satoh, and Shinichi Sugawara, and Chizuko Kuriyama, and Akio Kikuchi, and Masahiro Ohta
May 2020, Journal of medical case reports,
Copied contents to your clipboard!